DocGo Inc. (NASDAQ:DCGO) Q1 2024 Earnings Call Transcript

Norman Rosenberg: So, year-over-year, if I just look at those line items, it’s pretty flat. The reason for that is that while you are going to have transport growing by – from about 100 – the low 180s to the mid to high-190s, so maybe by 10% or so on the transport side. On the non-migrant mobile health, we had a couple of large municipal projects that were, I will call them, COVID-adjacent. They weren’t testing projects, but they were vaccination-related projects that we had in the first 3.5 months of 2023. That was probably $25 million or so and maybe another $5 million or $10 million of other projects that expired in the early part of 2023. So, when you look at that, then that number came down by a little bit. If you take that out, then it’s up by a bit. So, on a blended basis, we did about $300 million of what you would consider those core revenues last year and would expect to do $300 million this year.

David Grossman: Got it. Thanks. And then just on the segment margins, did you provide – is that in the Q, the segment EBITDA margins, any chance between transport and mobile?

Norman Rosenberg: The same way we have broken it out because we have the corporate. And I know that you guys apply – you apply the breakout of the corporate use, but yes, that’s all in there.

David Grossman: Great. Okay. That’s it for me.

Operator: Thank you, sir. Ladies and gentlemen, we have reached the end of our question-and-answer session. And I would like to turn the call back over to Lee Bienstock for closing remarks. Please go ahead, sir.

Lee Bienstock: Thank you and thank you all for joining today. We are looking forward to speaking with you again soon on all our progress. Be well.

Operator: Thank you, sir. Ladies and gentlemen, that then concludes today’s conference. Thank you for joining us. You may now disconnect your lines.